Your browser doesn't support javascript.
loading
Sepsis-trained macrophages promote antitumoral tissue-resident T cells.
Broquet, Alexis; Gourain, Victor; Goronflot, Thomas; Le Mabecque, Virginie; Sinha, Debajyoti; Ashayeripanah, Mitra; Jacqueline, Cédric; Martin, Pierre; Davieau, Marion; Boutin, Lea; Poulain, Cecile; Martin, Florian P; Fourgeux, Cynthia; Petrier, Melanie; Cannevet, Manon; Leclercq, Thomas; Guillonneau, Maeva; Chaumette, Tanguy; Laurent, Thomas; Harly, Christelle; Scotet, Emmanuel; Legentil, Laurent; Ferrières, Vincent; Corgnac, Stephanie; Mami-Chouaib, Fathia; Mosnier, Jean Francois; Mauduit, Nicolas; McWilliam, Hamish E G; Villadangos, Jose A; Gourraud, Pierre Antoine; Asehnoune, Karim; Poschmann, Jeremie; Roquilly, Antoine.
Affiliation
  • Broquet A; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Gourain V; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France.
  • Goronflot T; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Le Mabecque V; CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, Nantes Université, CIC 1413, Nantes, France.
  • Sinha D; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Ashayeripanah M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Jacqueline C; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Martin P; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Davieau M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Boutin L; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Poulain C; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France.
  • Martin FP; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Fourgeux C; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Petrier M; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France.
  • Cannevet M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Leclercq T; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France.
  • Guillonneau M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Chaumette T; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Laurent T; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France.
  • Harly C; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Scotet E; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Legentil L; Olgram SAS, Bréhan, France.
  • Ferrières V; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Corgnac S; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.
  • Mami-Chouaib F; Nantes Université, INSERM, CRC2INA, Nantes, France.
  • Mosnier JF; Nantes Université, INSERM, CRC2INA, Nantes, France.
  • Mauduit N; Ecole Nationale Supérieure de Chimie de Rennes, Université de Rennes, ISCR - UMR CNRS 6226, Rennes, France.
  • McWilliam HEG; Ecole Nationale Supérieure de Chimie de Rennes, Université de Rennes, ISCR - UMR CNRS 6226, Rennes, France.
  • Villadangos JA; INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculty de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • Gourraud PA; INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculty de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • Asehnoune K; CHU Nantes, Nantes Université, Anatomo-pathologie, Nantes, France.
  • Poschmann J; CHU Nantes, Nantes Université, PMSI, Nantes, France.
  • Roquilly A; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Nat Immunol ; 25(5): 802-819, 2024 May.
Article in En | MEDLINE | ID: mdl-38684922
ABSTRACT
Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Sepsis / Macrophages / Neoplasms Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Nat Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Sepsis / Macrophages / Neoplasms Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Nat Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Type: Article Affiliation country: France